#HVO hVIVO PLC – HCT contract signed with ILiAD Biotechnologies April 22, 2026 – Posted in: hVIVO (HVO)

· World’s first pivotal Phase III human challenge trial (“HCT”) in Bordetella pertussis (the bacteria that causes whooping cough) for ILiAD Biotechnologies vaccine candidate, BPZE1 · hVIVO’s largest HCT to date, with over 500 participants anticipated, with revenue recognition expected from H1 2026 · Trial expected to be hVIVO’s largest value HCT to date; making a strong contribution to near and mid‑term revenues with the majority expected to be recognised during 2026 and 2027 London, UK – 22 April 2026, hVIVO plc (AIM: HVO), a purpose-built,…

#HVO hVIVO PLC – £2m hMPV characterisation study contract February 17, 2025 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a fast-growing early-stage Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces that, following the success of its pilot human metapneumovirus (“hMPV”) characterisation trial announced in January 2025, it has signed a £2 million contract with a new biopharmaceutical client to complete the final stage of the characterisation study ahead of future hMPV human challenge trials (“HCTs”). The pilot characterisation trial produced a safe, measurable…

#HVO hVIVO PLC – Shionogi reports positive RSV trial results February 5, 2025 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a fast-growing early-stage Contract Research Organisation (“CRO”) and the world leader in human challenge clinical trials, notes the announcement by Shionogi & Co., Ltd. (“Shionogi”), reporting positive results from a Phase 2a Respiratory Syncytial Virus (“RSV”) human challenge trial (“HCT”) conducted by hVIVO. The trial demonstrated a significant reduction in viral load for Shionogi’s investigational oral RSV antiviral candidate, S-337395. S-337395, which has received Fast Track designation from the U.S.…

#HVO hVIVO PLC – Trading Update and Acquisition January 29, 2025 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a fast-growing specialist early-stage drug development contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, provides an unaudited trading update for the year ended 31 December 2024. Highlights · Revenue up 11.9% to £62.7 million (2023: £56.0 million) · EBITDA margin of c.26% (2023: 23.3%) · Cash of £44.2 million as at 31 December 2024 (31 December 2023: £37.0 million)…

#HVO hVIVO PLC – HCT contract signed with ILiAD Biotechnologies April 22, 2026 – Posted in: hVIVO (HVO)

#HVO hVIVO PLC – £2m hMPV characterisation study contract February 17, 2025 – Posted in: hVIVO (HVO)

#HVO hVIVO PLC – Shionogi reports positive RSV trial results February 5, 2025 – Posted in: hVIVO (HVO)

#HVO hVIVO PLC – Trading Update and Acquisition January 29, 2025 – Posted in: hVIVO (HVO)

Address

Contact

Social

LEGAL